1. Scrip
  2. >>R&D

ReNeuron Presses On With Stroke Therapy Development On Phase I Long-Term Benefits

 
• By Alexandra Shimmings

Long-term follow-up data from the Phase I PISCES study of ReNeuron's CTX cell therapy product build the case for pursuing the therapy as a potential stroke disability treatment.

MRI scan
• Source: Shutterstock

Further clinical testing of ReNeuron Group PLC's cell-based therapy CTX is warranted, experts say, after two-year follow-up data from its Phase I PISCES study just published in The Lancet showed that single intracerebral doses were associated with improved neurological function with no major adverse events.

The next important read-out for the product should come in the fourth quarter from the three-month follow-up point in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.